{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:30:36Z","timestamp":1791909036537,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T00:00:00Z","timestamp":1418169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10238-014-0322-5","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T12:00:14Z","timestamp":1418126414000},"page":"511-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus\u00a0patients"],"prefix":"10.1007","volume":"15","author":[{"given":"Gurusamy","family":"Umamaheswaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishnan Geethakumari","family":"Praveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solai Elango","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekaran","family":"Adithan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,10]]},"reference":[{"key":"322_CR1","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","volume":"29","author":"DM Nathan","year":"2006","unstructured":"Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2006;29:1963\u201372.","journal-title":"Diabetes Care"},{"key":"322_CR2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1517\/14656560903176453","volume":"10","author":"N Papanas","year":"2009","unstructured":"Papanas N, Maltezos E, Mikhailidis DP. Metformin: diamonds are forever. Expert Opin Pharmacother. 2009;10:2395\u20137.","journal-title":"Expert Opin Pharmacother"},{"key":"322_CR3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"322_CR4","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise M, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427\u201343.","journal-title":"N Engl J Med"},{"key":"322_CR5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1464-5491.1994.tb00253.x","volume":"11","author":"LS Hermann","year":"1994","unstructured":"Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med. 1994;11:953\u201360.","journal-title":"Diabet Med"},{"key":"322_CR6","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1172\/JCI32133","volume":"117","author":"ML Reitman","year":"2007","unstructured":"Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007;117:1226\u20139.","journal-title":"J Clin Invest"},{"key":"322_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10038-006-0087-0","volume":"52","author":"E Shikata","year":"2007","unstructured":"Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52:117\u201322.","journal-title":"J Hum Genet"},{"key":"322_CR8","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","volume":"117","author":"Y Shu","year":"2007","unstructured":"Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422\u201331.","journal-title":"J Clin Invest"},{"key":"322_CR9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/db08-0896","volume":"58","author":"K Zhou","year":"2009","unstructured":"Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58:1434\u20139.","journal-title":"Diabetes"},{"key":"322_CR10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/tpj.2009.15","volume":"9","author":"ML Becker","year":"2009","unstructured":"Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation inthe organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9:242\u20137.","journal-title":"Pharmacogenomics J"},{"key":"322_CR11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0971-6866.92094","volume":"17","author":"G Umamaheswaran","year":"2011","unstructured":"Umamaheswaran G, Praveen RG, Arunkumar AS, Das AK, Shewade DG, Adithan C. Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J Hum Genet. 2011;17:164\u20138.","journal-title":"Indian J Hum Genet"},{"key":"322_CR12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1463-1326.2012.01691.x","volume":"15","author":"I Tkac","year":"2013","unstructured":"Tkac I, Klimcakova L, Javorsky M, et al. Pharmacogenomic association betweena variant in SLC47A1 gene and therapeuticresponse to metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15:189\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"322_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/FPC.0b013e328333bb11","volume":"20","author":"ML Becker","year":"2010","unstructured":"Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010;20:38\u201344.","journal-title":"Pharmacogenet Genomics"},{"key":"322_CR14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FPC.0b013e3283561666","volume":"22","author":"L Tarasova","year":"2012","unstructured":"Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI inmetformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012;22:659\u201366.","journal-title":"Pharmacogenet Genomics"},{"key":"322_CR15","doi-asserted-by":"crossref","first-page":"686315","DOI":"10.1155\/2013\/686315","volume":"2013","author":"ML Becker","year":"2013","unstructured":"Becker ML, Pearson ER, Tkac I. Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol. 2013;2013:686315.","journal-title":"Int J Endocrinol"},{"key":"322_CR16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2174\/1389200214666131211153933","volume":"14","author":"S Chen","year":"2013","unstructured":"Chen S, Zhou J, Xi M, et al. Pharmacogenetic variation and metformin response. Curr Drug Metab. 2013;14:1070\u201382.","journal-title":"Curr Drug Metab"},{"key":"322_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng.735","volume":"43","author":"GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2","year":"2011","unstructured":"GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43:117\u201320.","journal-title":"Nat Genet"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-014-0322-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0322-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T07:37:40Z","timestamp":1559115460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-014-0322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1007\/s10238-014-0322-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,10]]}}}